Literature DB >> 31900074

Utility of lidocaine as a topical analgesic and improvements in patch delivery systems.

Jeff Gudin1,2, Sri Nalamachu3,4.   

Abstract

Interest in and use of topical analgesics has been increasing, presumably due to their potential utility for relief of acute and chronic pain. Topically applied agents with analgesic properties can target peripheral nociceptive pathways while minimizing absorption into the plasma that leads to potential systemic adverse effects.Clinical trials have found 5% lidocaine patches to be effective and well tolerated for the treatment of post-herpetic neuralgia (PHN) with a minimal risk of toxicity or drug-drug interactions. With this patch formulation, the penetration of lidocaine into the skin produces an analgesic effect without producing a complete sensory block. Use of topical lidocaine is supported by clinical practice guidelines, including first-line treatment by the American Academy of Neurology (guidelines retired 2018), the European Federation of Neurological Societies and second-line by the Canadian Pain Society.FDA approved 5% lidocaine patches in 1999, and a 1.8% topical lidocaine system in 2018 - both indicated for the treatment of pain secondary to PHN. The 1.8% system offers a more efficient delivery of lidocaine that is bioequivalent to 5% lidocaine patches, but with a 19-fold decrease in drug load (i.e., 36 mg versus 700 mg) as well as superior adhesion that allows the patch to maintain contact with the skin during the 12-h administration period.Although topical lidocaine formulations have advanced over time and play an important role in the treatment of PHN, a variety of other conditions that respond to topical lidocaine have been reported in the literature including PHN, lower back pain, carpal tunnel syndrome, diabetic peripheral neuropathy, and osteoarthritis joint pain. Other neuropathic or nociceptive pain syndromes may respond to topical lidocaine in select cases and warrant further study. Clinicians should consider local anesthetics and other topical agents as part of their multimodal treatments of acute and chronic pain.

Entities:  

Keywords:  Lidocaine; lidocaine patch; lidocaine plaster; lidocaine system; neuropathic pain; topical

Mesh:

Substances:

Year:  2020        PMID: 31900074     DOI: 10.1080/00325481.2019.1702296

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  13 in total

1.  Electrospun Nanofibers for Wound Management.

Authors:  Johnson V John; Alec McCarthy; Anik Karan; Jingwei Xie
Journal:  ChemNanoMat       Date:  2021-11-01       Impact factor: 3.820

2.  A Randomized, Crossover, Adhesion Performance and Pharmacokinetic Study of a Lidocaine Topical System Under Conditions of Water Exposure in Healthy Subjects.

Authors:  Kip Vought; Emileigh Greuber; Kalpana Patel; Charles Argoff; Dmitri Lissin
Journal:  J Pain Res       Date:  2021-08-16       Impact factor: 3.133

3.  Effects of vasopressin on anesthetic response time and circulatory dynamics of lidocaine.

Authors:  Shoko Fujimori; Katsuhisa Sunada
Journal:  Odontology       Date:  2021-01-15       Impact factor: 2.634

4.  Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects.

Authors:  Jeffrey Gudin; Lynn R Webster; Emileigh Greuber; Kip Vought; Kalpana Patel; Louis Kuritzky
Journal:  J Pain Res       Date:  2021-02-23       Impact factor: 3.133

5.  A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects.

Authors:  Jeffrey Gudin; Charles Argoff; Jeffrey Fudin; Emileigh Greuber; Kip Vought; Kalpana Patel; Sri Nalamachu
Journal:  J Pain Res       Date:  2020-06-22       Impact factor: 3.133

Review 6.  Considerations for lactation with Ehlers-Danlos syndrome: a narrative review.

Authors:  Jimi Francis; Darby D Dickton
Journal:  Int Breastfeed J       Date:  2022-01-04       Impact factor: 3.461

7.  Dexmedetomidine Co-Administered with Lidocaine Decreases Nociceptive Responses and Trigeminal Fos Expression without Motor Dysfunction and Hypotension in a Murine Orofacial Formalin Model.

Authors:  Ji-Hee Yeo; Dae-Hyun Roh
Journal:  Life (Basel)       Date:  2022-01-30

8.  Transdermal Delivery of Lidocaine-Loaded Elastic Nano-Liposomes with Microneedle Array Pretreatment.

Authors:  Yang Liu; Maosen Cheng; Junqi Zhao; Xiaoying Zhang; Zhen Huang; Yuhui Zang; Ying Ding; Junfeng Zhang; Zhi Ding
Journal:  Biomedicines       Date:  2021-05-23

9.  Biorelevant In Vitro Skin Permeation Testing and In Vivo Pharmacokinetic Characterization of Lidocaine from a Nonaqueous Drug-in-Matrix Topical System.

Authors:  Emileigh Greuber; Kip Vought; Kalpana Patel; Hiroaki Suzuki; Kazuhiro Usuda; Akira Shiramizu; Luana Pesco Koplowitz; Barry Koplowitz; Howard I Maibach; Dmitri Lissin
Journal:  AAPS PharmSciTech       Date:  2021-08-12       Impact factor: 3.246

10.  Preparation and In Vivo Evaluation of a Lidocaine Self-Nanoemulsifying Ointment with Glycerol Monostearate for Local Delivery.

Authors:  Ji-Hyun Kang; Kwang-Hwi Yoo; Hyo-Young Park; Seung-Min Hyun; Sang-Duk Han; Dong-Wook Kim; Chun-Woong Park
Journal:  Pharmaceutics       Date:  2021-09-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.